Literature DB >> 11801222

Sensitivities of Leishmania species to hexadecylphosphocholine (miltefosine), ET-18-OCH(3) (edelfosine) and amphotericin B.

Patricia Escobar1, Sangeeta Matu, Cláudia Marques, Simon L Croft.   

Abstract

The sensitivities of both promastigote and amastigote stages of six species of Leishmania, L. donovani, L. major, L. tropica, L. aethiopica, L. mexicana and L. panamensis, were determined in vitro to the phospholipid drugs hexadecylphosphocholine (HPC, miltefosine) and ET-18-OCH(3) (edelfosine). In all assays L. donovani was the most sensitive species, with ED(50) values in the range of 0.12-1.32 microM against promastigotes and 1.2-4.6 microM against amastigotes. L. major was the least sensitive species in the majority of assays with ED(50) values for HPC in the range of 4.8-13.1 microM against promastigotes and for HPC and ET-18-OCH(3) in the range of 7.5-37.1 microM against amastigotes. Amphotericin B deoxycholate was used as the standard drug and gave submicromolar ED(50) values in all assays; L. mexicana was the least sensitive species to this drug.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11801222     DOI: 10.1016/s0001-706x(01)00197-8

Source DB:  PubMed          Journal:  Acta Trop        ISSN: 0001-706X            Impact factor:   3.112


  70 in total

1.  Proinflammatory and cytotoxic effects of hexadecylphosphocholine (miltefosine) against drug-resistant strains of Trypanosoma cruzi.

Authors:  Victor B Saraiva; Daniel Gibaldi; José O Previato; Lucia Mendonça-Previato; Marcelo T Bozza; Célio G Freire-De-Lima; Norton Heise
Journal:  Antimicrob Agents Chemother       Date:  2002-11       Impact factor: 5.191

2.  Identification of new antileishmanial leads from hits obtained by high-throughput screening.

Authors:  Xiaohua Zhu; Trupti Pandharkar; Karl Werbovetz
Journal:  Antimicrob Agents Chemother       Date:  2011-12-05       Impact factor: 5.191

3.  Reductions in skin and systemic parasite burdens as a combined effect of topical paromomycin and oral miltefosine treatment of mice experimentally infected with Leishmania (Leishmania) amazonensis.

Authors:  Marta Gontijo Aguiar; Aline Márcia Machado Pereira; Ana Paula Fernandes; Lucas Antonio Miranda Ferreira
Journal:  Antimicrob Agents Chemother       Date:  2010-08-16       Impact factor: 5.191

4.  In vitro activity of perifosine: a novel alkylphospholipid against the promastigote stage of Leishmania species.

Authors:  María Gabriela Cabrera-Serra; Jacob Lorenzo-Morales; Marialina Romero; Basilio Valladares; José E Piñero
Journal:  Parasitol Res       Date:  2007-01-06       Impact factor: 2.289

Review 5.  Drug resistance in leishmaniasis.

Authors:  Simon L Croft; Shyam Sundar; Alan H Fairlamb
Journal:  Clin Microbiol Rev       Date:  2006-01       Impact factor: 26.132

6.  Functional Validation of ABCA3 as a Miltefosine Transporter in Human Macrophages: IMPACT ON INTRACELLULAR SURVIVAL OF LEISHMANIA (VIANNIA) PANAMENSIS.

Authors:  Luuk C T Dohmen; Adriana Navas; Deninson Alejandro Vargas; David J Gregory; Anke Kip; Thomas P C Dorlo; Maria Adelaida Gomez
Journal:  J Biol Chem       Date:  2016-02-22       Impact factor: 5.157

7.  Miltefosine (Impavido): the first oral treatment against leishmaniasis.

Authors:  H Sindermann; S L Croft; K R Engel; W Bommer; H J Eibl; C Unger; J Engel
Journal:  Med Microbiol Immunol       Date:  2003-09-26       Impact factor: 3.402

8.  Amphotericin B-loaded nanoparticles for local treatment of cutaneous leishmaniasis.

Authors:  Aiman Abu Ammar; Abed Nasereddin; Suheir Ereqat; Mary Dan-Goor; Charles L Jaffe; Eyal Zussman; Ziad Abdeen
Journal:  Drug Deliv Transl Res       Date:  2019-02       Impact factor: 4.617

9.  Low plasma membrane expression of the miltefosine transport complex renders Leishmania braziliensis refractory to the drug.

Authors:  María P Sánchez-Cañete; Luís Carvalho; F Javier Pérez-Victoria; Francisco Gamarro; Santiago Castanys
Journal:  Antimicrob Agents Chemother       Date:  2009-02-02       Impact factor: 5.191

10.  Drug resistance in leishmaniasis.

Authors:  Jaya Chakravarty; Shyam Sundar
Journal:  J Glob Infect Dis       Date:  2010-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.